Učitavanje...
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (...
Spremljeno u:
| Izdano u: | Ther Adv Respir Dis |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144513/ https://ncbi.nlm.nih.gov/pubmed/30215300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618794133 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|